Skip to main content
Top
Published in: BMC Ophthalmology 1/2015

Open Access 01-12-2015 | Technical advance

Outcome measure for the treatment of cone photoreceptor diseases: orientation to a scene with cone-only contrast

Authors: Alejandro J. Roman, Artur V. Cideciyan, Rodrigo Matsui, Rebecca Sheplock, Sharon B. Schwartz, Samuel G. Jacobson

Published in: BMC Ophthalmology | Issue 1/2015

Login to get access

Abstract

Background

Inherited retinal degenerations (IRDs) preferentially affecting cone photoreceptor function are being considered for treatment trials aiming to improve day vision. The purpose of the current work was to develop cone-specific visual orientation outcomes that can differentiate day vision improvement in the presence of retained night vision.

Methods

A lighted wall (1.4 m wide, 2 m high) resembling a beaded curtain was formed with 900 individually addressable red, blue and green LED triplets placed in 15 vertical strips hanging 0.1 m apart. Under computer control, different combination of colors and intensities were used to produce the appearance of a door on the wall. Scotopically-matched trials were designed to be perceptible to the cone-, but not rod-, photoreceptor based visual systems. Unmatched control trials were interleaved at each luminance level to determine the existence of any vision available for orientation. Testing started with dark-adapted eyes and a scene luminance attenuated 8 log units from the maximum attainable, and continued with progressively increasing levels of luminance. Testing was performed with a three-alternative forced choice method in healthy subjects and patients with Leber congenital amaurosis (LCA) caused by mutations in GUCY2D, the gene that encodes retinal guanylate cyclase-1.

Results

Normal subjects could perform the orientation task using cone vision at 5 log attenuation and brighter luminance levels. Most GUCY2D-LCA patients failed to perform the orientation task with scotopically-matched test trials at any luminance level even though they were able to perform correctly with unmatched control trials. These results were consistent with a lack of cone system vision and use of the rod system under ambient conditions normally associated with cone system activity. Two GUCY2D-LCA patients demonstrated remnant cone vision but at a luminance level 2 log brighter than normal.

Conclusions

The newly developed device can probe the existence or emergence of cone-based vision in patients for an orientation task involving the identification of a door on the wall under free-viewing conditions. This key advance represents progress toward developing an appropriate outcome measure for a clinical trial to treat currently incurable eye diseases severely affecting cone vision despite retained rod vision.
Literature
1.
go back to reference Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci. 2010;33:441–72.CrossRefPubMed Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci. 2010;33:441–72.CrossRefPubMed
2.
go back to reference Thompson DA, Ali RR, Banin E, Branham KE, Flannery JG, Gamm DM, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56(2):918–31.CrossRefPubMedPubMedCentral Thompson DA, Ali RR, Banin E, Branham KE, Flannery JG, Gamm DM, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56(2):918–31.CrossRefPubMedPubMedCentral
3.
go back to reference Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297–305.CrossRefPubMed Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297–305.CrossRefPubMed
4.
go back to reference Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, et al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 2014;132(7):866–73.CrossRefPubMedPubMedCentral Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, et al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 2014;132(7):866–73.CrossRefPubMedPubMedCentral
5.
go back to reference Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105(39):15112–7.CrossRefPubMedPubMedCentral Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105(39):15112–7.CrossRefPubMedPubMedCentral
6.
go back to reference Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920–6.CrossRefPubMedPubMedCentral Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920–6.CrossRefPubMedPubMedCentral
7.
go back to reference Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9–24.CrossRefPubMed Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9–24.CrossRefPubMed
8.
go back to reference Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, et al. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012;119(4):779–88.CrossRefPubMedPubMedCentral Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, et al. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012;119(4):779–88.CrossRefPubMedPubMedCentral
9.
go back to reference Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol. 2006;51(3):232–58.CrossRefPubMed Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol. 2006;51(3):232–58.CrossRefPubMed
11.
go back to reference Zelinger L, Cideciyan AV, Kohl S, Schwartz SB, Rosenmann A, Eli D, et al. Genetics and disease expression in the CNGA3 form of achromatopsia: steps on the path to gene therapy. Ophthalmology. 2015;122(5):997–1007.CrossRefPubMed Zelinger L, Cideciyan AV, Kohl S, Schwartz SB, Rosenmann A, Eli D, et al. Genetics and disease expression in the CNGA3 form of achromatopsia: steps on the path to gene therapy. Ophthalmology. 2015;122(5):997–1007.CrossRefPubMed
12.
go back to reference Roosing S, Thiadens AA, Hoyng CB, Klaver CC, den Hollander AI, Cremers FP. Causes and consequences of inherited cone disorders. Prog Retin Eye Res. 2014;42:1–26.CrossRefPubMed Roosing S, Thiadens AA, Hoyng CB, Klaver CC, den Hollander AI, Cremers FP. Causes and consequences of inherited cone disorders. Prog Retin Eye Res. 2014;42:1–26.CrossRefPubMed
13.
go back to reference Cideciyan AV, Hufnagel RB, Carroll J, Sumaroka A, Luo X, Schwartz SB, et al. Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther. 2013;24(12):993–1006.CrossRefPubMedPubMedCentral Cideciyan AV, Hufnagel RB, Carroll J, Sumaroka A, Luo X, Schwartz SB, et al. Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther. 2013;24(12):993–1006.CrossRefPubMedPubMedCentral
14.
go back to reference Luo X, Cideciyan AV, Iannaccone A, Roman AJ, Ditta LC, Jennings BJ, et al. Blue cone monochromacy: visual function and efficacy outcome measures for clinical trials. PLoS One 2015. doi:10.1371/journal.pone.0125700 Luo X, Cideciyan AV, Iannaccone A, Roman AJ, Ditta LC, Jennings BJ, et al. Blue cone monochromacy: visual function and efficacy outcome measures for clinical trials. PLoS One 2015. doi:10.​1371/​journal.​pone.​0125700
15.
go back to reference Fishman GA, Stone EM, Eliason DA, Taylor CM, Lindeman M, Derlacki DJ. ABCA4 gene sequence variations in patients with autosomal recessive cone-rod dystrophy. Arch Ophthalmol. 2003;121(6):851–5.CrossRefPubMed Fishman GA, Stone EM, Eliason DA, Taylor CM, Lindeman M, Derlacki DJ. ABCA4 gene sequence variations in patients with autosomal recessive cone-rod dystrophy. Arch Ophthalmol. 2003;121(6):851–5.CrossRefPubMed
16.
go back to reference Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, Traboulsi EI, et al. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. Ophthalmology. 2010;117(6):1190–8.CrossRefPubMed Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, Traboulsi EI, et al. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. Ophthalmology. 2010;117(6):1190–8.CrossRefPubMed
17.
go back to reference Jacobson SG, Cideciyan AV, Peshenko IV, Sumaroka A, Olshevskaya EV, Cao L, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet. 2013;22(1):168–83.CrossRefPubMed Jacobson SG, Cideciyan AV, Peshenko IV, Sumaroka A, Olshevskaya EV, Cao L, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet. 2013;22(1):168–83.CrossRefPubMed
18.
go back to reference Williams ML, Coleman JE, Haire SE, Aleman TS, Cideciyan AV, Sokal I, et al. Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med. 2006;3(6):e201.CrossRefPubMedPubMedCentral Williams ML, Coleman JE, Haire SE, Aleman TS, Cideciyan AV, Sokal I, et al. Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med. 2006;3(6):e201.CrossRefPubMedPubMedCentral
19.
go back to reference Boye SL, Peshenko IV, Huang WC, Min SH, McDoom I, Kay CN, et al. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther. 2013;24(2):189–202.CrossRefPubMed Boye SL, Peshenko IV, Huang WC, Min SH, McDoom I, Kay CN, et al. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther. 2013;24(2):189–202.CrossRefPubMed
20.
go back to reference Treutwein B, Strasburger H. Fitting the psychometric function. Percept Psychophys. 1999;61:87–106.CrossRefPubMed Treutwein B, Strasburger H. Fitting the psychometric function. Percept Psychophys. 1999;61:87–106.CrossRefPubMed
21.
go back to reference Geruschat DR, Flax M, Tanna N, Bianchi M, Fisher A, Goldschmidt M, et al. FLORA™: Phase I development of a functional vision assessment for prosthetic vision users. Clin Exp Optom. 2015;98(4):342–47. Geruschat DR, Flax M, Tanna N, Bianchi M, Fisher A, Goldschmidt M, et al. FLORA™: Phase I development of a functional vision assessment for prosthetic vision users. Clin Exp Optom. 2015;98(4):342–47.
22.
go back to reference Nau A, Bach M, Fisher C. Clinical tests of ultra-low vision used to evaluate rudimentary visual perceptions enabled by the BrainPort vision device. Transl Vis Sci Technol. 2013;2(3):1.CrossRefPubMedPubMedCentral Nau A, Bach M, Fisher C. Clinical tests of ultra-low vision used to evaluate rudimentary visual perceptions enabled by the BrainPort vision device. Transl Vis Sci Technol. 2013;2(3):1.CrossRefPubMedPubMedCentral
23.
go back to reference Apfelbaum H, Pelah A, Peli E. Heading assessment by "tunnel vision" patients and control subjects standing or walking in a virtual reality environment. ACM Trans Appl Percept. 2007;4(1):8.CrossRefPubMedPubMedCentral Apfelbaum H, Pelah A, Peli E. Heading assessment by "tunnel vision" patients and control subjects standing or walking in a virtual reality environment. ACM Trans Appl Percept. 2007;4(1):8.CrossRefPubMedPubMedCentral
24.
go back to reference Bowers AR, Ananyev E, Mandel AJ, Goldstein RB, Peli E. Driving with hemianopia: IV. Head scanning and detection at intersections in a simulator. Invest Ophthalmol Vis Sci. 2014;55(3):1540–8.CrossRefPubMedPubMedCentral Bowers AR, Ananyev E, Mandel AJ, Goldstein RB, Peli E. Driving with hemianopia: IV. Head scanning and detection at intersections in a simulator. Invest Ophthalmol Vis Sci. 2014;55(3):1540–8.CrossRefPubMedPubMedCentral
25.
go back to reference Kolarik AJ, Cirstea S, Pardhan S, Moore BC. A summary of research investigating echolocation abilities of blind and sighted humans. Hear Res. 2014;310:60–8.CrossRefPubMed Kolarik AJ, Cirstea S, Pardhan S, Moore BC. A summary of research investigating echolocation abilities of blind and sighted humans. Hear Res. 2014;310:60–8.CrossRefPubMed
26.
go back to reference Markowitz M. Occupational therapy interventions in low vision rehabilitation. Can J Ophthalmol. 2006;41(3):340–7.CrossRefPubMed Markowitz M. Occupational therapy interventions in low vision rehabilitation. Can J Ophthalmol. 2006;41(3):340–7.CrossRefPubMed
27.
go back to reference Black A, Lovie-Kitchin J, Woods R, Arnold N, Byrnes J, Murrish J. Mobility performance with retinitis pigmentosa. Clin Exp Optom. 1996;80(1):1–12.CrossRef Black A, Lovie-Kitchin J, Woods R, Arnold N, Byrnes J, Murrish J. Mobility performance with retinitis pigmentosa. Clin Exp Optom. 1996;80(1):1–12.CrossRef
28.
go back to reference Geruschat DR, Turano KA, Stahl JW. Traditional measures of mobility performance and retinitis pigmentosa. Optom Vis Sci. 1998;75(7):525–37.CrossRefPubMed Geruschat DR, Turano KA, Stahl JW. Traditional measures of mobility performance and retinitis pigmentosa. Optom Vis Sci. 1998;75(7):525–37.CrossRefPubMed
29.
go back to reference Kuyk T, Elliott JL, Fuhr PS. Visual correlates of obstacle avoidance in adults with low vision. Optom Vis Sci. 1998;75(3):174–82.CrossRefPubMed Kuyk T, Elliott JL, Fuhr PS. Visual correlates of obstacle avoidance in adults with low vision. Optom Vis Sci. 1998;75(3):174–82.CrossRefPubMed
30.
go back to reference Haymes S, Guest D, Heyes A, Johnston A. Comparison of functional mobility performance with clinical vision measures in simulated retinitis pigmentosa. Optom Vis Sci. 1994;71(7):442–53.CrossRefPubMed Haymes S, Guest D, Heyes A, Johnston A. Comparison of functional mobility performance with clinical vision measures in simulated retinitis pigmentosa. Optom Vis Sci. 1994;71(7):442–53.CrossRefPubMed
31.
go back to reference Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, Dollfus H, et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet. 1996;14(4):461–4.CrossRefPubMed Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, Dollfus H, et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet. 1996;14(4):461–4.CrossRefPubMed
32.
go back to reference den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27(4):391–419.CrossRef den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27(4):391–419.CrossRef
33.
go back to reference Boye SE. Leber congenital amaurosis caused by mutations in GUCY2D. Cold Spring Harb Perspect Med. 2014;5(1):a017350.CrossRefPubMed Boye SE. Leber congenital amaurosis caused by mutations in GUCY2D. Cold Spring Harb Perspect Med. 2014;5(1):a017350.CrossRefPubMed
34.
go back to reference Velikay-Parel M, Ivastinovic D, Koch M, Hornig R, Dagnelie G, Richard G, et al. Repeated mobility testing for later artificial visual function evaluation. J Neural Eng. 2007;4(1):S102–107.CrossRefPubMed Velikay-Parel M, Ivastinovic D, Koch M, Hornig R, Dagnelie G, Richard G, et al. Repeated mobility testing for later artificial visual function evaluation. J Neural Eng. 2007;4(1):S102–107.CrossRefPubMed
Metadata
Title
Outcome measure for the treatment of cone photoreceptor diseases: orientation to a scene with cone-only contrast
Authors
Alejandro J. Roman
Artur V. Cideciyan
Rodrigo Matsui
Rebecca Sheplock
Sharon B. Schwartz
Samuel G. Jacobson
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2015
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-015-0085-0

Other articles of this Issue 1/2015

BMC Ophthalmology 1/2015 Go to the issue